CROI 2015 Program and Abstracts

Oral Sessions

THURSDAY, FEBRUARY 26, 2015

140 Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors Grace A. McComsey 1 ; Carlee Moser 2 ; Judith S. Currier 8 ; Heather Ribaudo 2 ; Pawel Paczuski 2 ; Michael P. Dube 5 ; Robert L. Murphy 6 ; Jennifer Rothenberg 7 ; James H. Stein 4 ;ToddT. Brown 3 1 Case Western Reserve University, Cleveland, OH, US; 2 Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3 Johns Hopkins University School of Medicine, Baltimore, MD, US; 4 University of Wisconsin School of Medicine and Public Health, Madison, WI, US; 5 University of Southern California, Los Angeles, CA, US; 6 Northwestern University, Chicago, IL, US; 7 Social & Scientific Systems, Inc., Silver Spring, MD, US; 8 University of California Los Angeles, Los Angeles, CA, US 141 Fracture PredictionWith Modified FRAX in Older HIV+ and HIV- Men Michael T. Yin 1 ; Melissa Skanderson 7 ; Stephanie Shiau 1 ; Katherine Harwood 1 ; Josh Aschheim 3 ; David Rimland 2 ; Cynthia Gibert 5 ; Maria Rodriguez-Barradas 4 ; Roger Bedimo 6 ; JulieWomack 7 1 Columbia University Medical Center, New York, NY, US; 2 VAMC and Emory School of Medicine, Atlanta, GA, US; 3 Arcadia Healthcare Solutions, New York, NY, US; 4 Baylor College of Medicine, Houston, TX, US; 5 VA Medical Center, George Washington University, Washington, DC, US; 6 University of Texas, Dallas, TX, US; 7 VA Connecticut Healthcare System, West Haven, CT, US 142 Exposure to Antiretrovirals (ARVs) and Development of Chronic Kidney Disease (CKD) Amanda Mocroft 1 ; Jens D. Lundgren 2 ; Michael Ross 3 ; Christoph Fux 4 ; Peter Reiss 5 ; Olivier Moranne 6 ; Philippe Morlat 7 ; Antonella d’Arminio Monforte 8 ; Ole Kirk 2 ; Lene Ryom 2 On behalf of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group 1 University College London, London, United Kingdom; 2 Copenhagen HIV Programme, Centre for Health and Infectious Diseases Network, University of Copenhagen, Denmark, Denmark; 3 Division of Nephrology, Mount Sinai School of Medicine, New York, NY, US; 4 Clinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Aarau, Switzerland; 5 Academic Medical Center, Div. of Infectious Diseases and Dept. of Global Health, University of Amsterdam, Amsterdam, Netherlands; 6 Université de Bordeaux, Inserm U 897, Bordeaux, France; 7 Public Health Department, Nice, France; 8 Istituto Di Clinica Malattie Infettive e Tropicale, Milan, Italy 143LB Renal and Bone Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate Paul E. Sax 7 ; Michael S. Saag 2 ; MichaelT.Yin 3 ; Frank A. Post 4 ; Shinichi Oka 8 ; Ellen Koenig 5 ; BenoitTrottier 9 ; Jaime Andrade-Villanueva 6 ; Huyen Cao 1 ; MarshallW. Fordyce 1 1 Gilead Sciences Inc, Foster City, CA, US; 2 University of Alabama at Birmingham, Birmingham, AL, US; 3 College of Physicians and Surgeons, Columbia University, New York, NY, US; 4 King’s College Hospital, London, United Kingdom; 5 Dominican Institute for Virologic Studies, Santo Domingo, Dominican Republic; 6 Unidad de VIH del Hospital Civil de Guadalajara, Guadalajara, Mexico; 7 Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, US; 8 National Center for Global Health and Medicine, Japan, Tokyo, Japan; 9 Clinique Medicale l’Actuel, Montreal, Canada 144 Special Presentation: Update on National Heart, Lung, and Blood Institute High-Impact AIDS Research Monica Shah National Heart, Lung, and Blood Institute, Bethesda, MD, US Session O-12 Oral Abstracts Room 6AB 10:00 am– 12:00 pm Curing HCV: Mission Accomplished Moderators Karine Lacombe , Saint Antoine Hospital, AP-HP, Paris, France John W. Ward , Centers for Disease Control and Prevention, Atlanta, GA, US 145 The Burden of Liver Disease Among Persons With Hepatitis C in the United States Monina Klevens 1 ; Xiaohua Huang 2 ; Anthony E.Yeo 2 ; Mouneer Odeh 2 ; Rick L. Pesano 2 ; John W.Ward 1 1 US Centers for Disease Control and Prevention, Atlanta, GA, US; 2 Quest Diagnostics, Madison, NJ, US 146 High Efficacy of Daclatasvir/Asunaprevir/PR in HIV/HCV1-4 Null Responders (ANRS HC30) Lionel Piroth 1 ; Hubert Paniez 2 ; CorineVincent 2 ; Karine Lacombe 3 ; David Rey 4 ; Didier Neau 5 ; Jacques Izopet 6 ; Alpha Diallo 7 ; Laurence Meyer 2 ; Jean-Michel Molina 8 1 CHU Dijon, Dijon, France; 2 Inserm, Paris, France; 3 Hôpital Saint-Antoine, Paris, France; 4 Strasbourg University Hospital, Strasbourg, France; 5 CHU, Bordeaux, France; 6 CHU, Toulouse, France; 7 Inserm-ANRS, Paris, France; 8 CHU Saint Louis, Paris, France

Session PL-1 Plenary

4AB Auditorium

8:30 am– 9:00 am Cardiovascular Disease in HIV Patients: An Emerging Paradigm and Call to Action 134 Cardiovascular Disease in HIV Patients: An Emerging Paradigm and Call to Action Steven Grinspoon Massachusetts General Hospital, Harvard Medical School, Boston, MA, US Session PL-2 Plenary 4AB Auditorium 9:00 am– 9:30 am The Price of Selling Sex: HIV Among Female Sex Workers—The Context and the Public Health Response 135 The Price of Selling Sex: HIV Among Female Sex Workers— The Context and the Public Health Response Frances M. Cowan University College London, London, United Kingdom Session O-11 Oral Abstracts Room 6C 10:00 am– 12:15 pm Cardiovascular, Bone, and Kidney Health Moderators Jennifer F. Hoy , The Alfred Hospital and Monash University, Melbourne, Victoria, Australia Edgar T. Overton , University of Alabama at Birmingham, Birmingham, AL, US 136 Statin Therapy Reduces Coronary Noncalcified Plaque Volume in HIV Patients: A Randomized Controlled Trial Janet Lo 1 ; Michael Lu 2 ; Ezinne Ihenachor 1 ; JeffreyWei 1 ; Sara Looby 1 ; Kathleen Fitch 1 ; Suhny Abbara 2 ; Gregory Robbins 1 ; Udo Hoffmann 2 ; Steven Grinspoon 1 1 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2 Massachusetts General Hospital, Boston, MA, US 137 Rosuvastatin Arrests Progression of Carotid Intima-Media Thickness in Treated HIV ChrisT. Longenecker 1 ;Ying Jiang 1 ; Sara M. Debanne 1 ; Danielle Labbato 2 ; Bruce Kinley 2 ; Norma Storer 2 ; Grace A. McComsey 1 1 Case Western Reserve University, Cleveland, OH, US; 2 University Hospitals of Cleveland, Cleveland, OH, US 138 Calcified Plaque Burden Is AssociatedWith Serum Gut Microbiota- Generated TMA in HIV Suman Srinivasa 1 ; KathleenV. Fitch 1 ; Janet Lo 1 ; Hanane Kadar 2 ; KimberlyWong 1 ; Suhny Abbara 3 ; Dominique Gauguier 2 ; Jacqueline Capeau 2 ; Franck Boccara 2 ; Steven K. Grinspoon 1 1 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2 University Pierre & Marie Curie, Paris, France; 3 University of Texas Southwestern Medical Center, Dallas, TX, US 139 Varenicline vs Placebo for Smoking Cessation: ANRS 144 Inter-ACTIV Randomized Trial Patrick Mercie 3 ; Caroline Roussillon 1 ; Christine Katlama 4 ; Aurélie Beuscart 1 ; Samuel Ferret 2 ; NathalieWirth 5 ; David Zucman 6 ; Xavier Duval 7 ; Genevieve Chene 1 On behalf of the ANRS 144 inter-ACTIV study group 1 Inserm U897, Bordeaux, France; 2 Hosp. Saint-Louis, Paris, France; 3 Hosp. Saint-André, Bordeaux, France; 4 Hosp. La Pitié-Salpêtrière, Paris, France; 5 Hosp. De Brabois, Vandoeuvre les Nancy, France; 6 Hosp. Foch, Suresnes, France; 7 CIC 1425, Paris, France

Thursday, February 26, 2015 • Oral Sessions

16

CROI 2015